Inmune Bio, Inc. Cash Flow Statement
INMB|7 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Inmune Bio, Inc. used $33M in operating cash flow and negative free cash flow of $34M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|
| Net Income | -$42.1M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M | -$831.5K |
| Depreciation & Amortization | $84.0K | - | - | - | - | - | - |
| Operating Cash Flow | -$33.4M | -$12.0M | -$22.7M | -$28.5M | -$8.9M | -$5.4M | -$761.8K |
| Capital Expenditures | $1.0M | - | - | - | - | - | - |
| Free Cash Flow | -$34.4M | - | - | - | - | - | - |
| FCF Margin | -245735.7% | - | - | - | - | - | - |